As we expected, the efficacy of TACE treatment in these 4 patients was relatively poor, and their PFS was significantly shorter than HCC patients without NQO1 amplification (median survival 83 versus 158 days, P = 0.020; Fig. 3I,J). Here, NQO1 is linked to hepatocellular carcinoma.